Recent Updates
Recently added Catalysts
XENE Positive Sentiment

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Friday, October 6, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xenon Pharmaceuticals Inc. announced it will present at the Jefferies Inaugural Biotech CNS/Neuro Summit on October 11, 2023. The presentation will feature CEO Ian Mortimer and CFO Sherry Aulin. A live webcast of the event will be available, allowing audiences to participate and learn about Xenon's advancements in neurology-focused therapeutics. The company emphasizes its commitment to addressing unmet medical needs in neurological disorders.
Price reaction · baseline $35.17 (2023-10-05 close) · hit after-hours · 1 other XENE headline(s) in the window, move may be shared
day 0 close · peak
+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xenon Pharmaceuticals will present at a notable industry summit.
  • The presentation will highlight innovative therapeutics in neurology.
  • The event provides a platform for increasing visibility and engagement in the biotech community.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
14.4%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
XPF-001
Phase 1 · Primary Erythromelalgia

Full Press Release Details

VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Jefferies Inaugural Biotech CNS/Neuro Summit to be held on October 11, 2023.
Company Fireside Chat Presentation Details:
Date: Wednesday, October 11, 2023
Time: 2:25 PM Eastern Time
Webcast: Register here
Presenters: Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financial Officer
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Xenon Pharmaceuticals Inc.

Frequently Asked Questions

When will Xenon Pharmaceuticals present at the Jefferies Summit?

Xenon Pharmaceuticals will present on October 11, 2023.

Who are the presenters for Xenon's fireside chat?

Ian Mortimer and Sherry Aulin will present.

What is the focus of Xenon Pharmaceuticals?

Xenon focuses on developing therapies for neurological disorders.

How can I watch the Xenon presentation?

The presentation can be streamed live on Xenon's website.

What condition does Xenon primarily target?

Xenon primarily targets epilepsy in its therapeutic development.

ShareAdd on Google
Tags: XENE Viatris Investor Conferences Healthcare Xenon Pharmaceuticals CNS Summit neurology biotech
Last updated: Oct 6, 2023

Biotech snapshot

Cash runway
$1245M liquidity · $32M/mo burn
~39 mo
Minimal dilution risk
Lead asset
XPF-001Phase 1
Primary Erythromelalgia →

Catalyst track record

+56%
best trade around XENE's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for XENE.

See every catalyst's timing & PoA →